Microbial translocation and microbiome dysbiosis in HIV-associated immune activation

Current Opinion in HIV and AIDS

Volumn 11, Issue 2, 2016, Pages 182-190

  Zevin, Alexander S ^a,b   McKinnon, Lyle ^c,d   Burgener, Adam ^d,e,f   Klatt, Nichole R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Washington National Primate Research Center   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF MANITOBA   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HIV AIDS; inflammation; microbial translocation; microbiome; mucosal

Indexed keywords

BACTERIAL IMMUNITY; BACTERIAL TRANSLOCATION; BACTEROIDES; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; DYSBIOSIS; GASTROINTESTINAL TRACT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LAMINA PROPRIA; MICROBIAL COMMUNITY; MICROBIAL DYSBIOSIS; MICROBIAL TRANSLOCATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; PATHOPHYSIOLOGY;

BACTERIAL TRANSLOCATION; DYSBIOSIS; HIV INFECTIONS; HUMANS; INFLAMMATION; MICROBIOTA;

EID: 84957433925     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000234     Document Type: Review

References (108)

1. Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Curr Opin Immunol 2015; 36: 22-30.
2. Somsouk M, Estes JD, Deleage C, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS 2015; 29: 43-51.
3. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280: 427-431.
4. Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434: 1093-1097.
5. Macal M, Sankaran S, Chun TW, et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 2008; 1: 475-488.
6. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1: 23-30.
7. Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol 2007; 127: 2525-2532.
8. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809.
9. Arnold KB, Burgener A, Birse K, et al. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIVsusceptible target cells. Mucosal Immunol 2015. doi: 10.1038/mi.2015.51.
10. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10: e1004543.
11. McKinnon LR, Nyanga B, Kim CJ, et al. Early HIV-1 infection is associated with reduced frequencies of cervical Th17 cells. J Acquir Immune Defic Syndr 2015; 68: 6-12.
12. Raffatellu M, Santos RL, Verhoeven DE, et al. Simian immunodeficiency virusinduced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008; 14: 421-428.
13. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173-182.
14. Estes JD, Harris LD, Klatt NR, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 2010; 6: e1001052.
15. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 2014; 10: e1003890.
16. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6: e1000852.
17. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol 2008; 82: 538-545.
18. McGowan I, Radford-Smith G, Jewell DP. Cytokine gene expression in HIVinfected intestinal mucosa. AIDS 1994; 8: 1569-1575.
19. Hirao LA, Grishina I, BourryO, et al. Early mucosal sensing of SIV infection by paneth cells induces IL-1beta production and initiates gut epithelial disruption. PLoS Pathog 2014; 10: e1004311.
20. Poles MA, Fuerst M, McGowan I, et al. HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. Am J Gastroenterol 2001; 96: 1831-1837.
21. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
22. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7: 235-239.
23. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21: 6-13.
24. Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474: 327-336.
25. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230.
26. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
27. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200: 973-983.
28. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
29. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS Patients. PLoS One 2008; 3: e2516.
30. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202: 723-733.
31. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199: 1177-1185.
32. Canary LA, Vinton CL, Morcock DR, et al. Rate of AIDS progression is associated with gastrointestinal dysfunction in simian immunodeficiency virus-infected pigtail macaques. J Immunol 2013; 190: 2959-2965.
33. Funderburg N, Luciano AA, Jiang W, et al. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 2008; 3: e1915.
34. Lee PI, Ciccone EJ, Read SW, et al. Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis 2009; 199: 1664-1670.
35. Klatt NR, Harris LD, Vinton CL, et al. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol 2010; 3: 387-398.
36. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210: 1228-1238.
37. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5: 193ra191.
38. Klase Z, Ortiz A, Deleage C, et al. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol 2015; 8: 1009-1020.
39. Thaiss CA, Levy M, Suez J, Elinav E. The interplay between the innate immune system and the microbiota. Curr Opin Immunol 2014; 26: 41-48.
40. Dalmasso M, Hill C, Ross RP. Exploiting gut bacteriophages for human health. Trends Microbiol 2014; 22: 399-405.
41. Oever JT, Netea MG. The bacteriome-mycobiome interaction and antifungal host defense. Eur J Immunol 2014; 44: 3182-3191.
42. Pimentel M, Gunsalus RP, Rao SSC, Zhang H. Methanogens in human health and disease. Am J Gastroenterol Suppl 2012; 1: 28-33.
43. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014; 7: 983-994.
44. Lozupone CA, Li M, Campbell TB, et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 2013; 14: 329-339.
45. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10: e1003829.
46. McHardy IH, Li X, Tong M, et al. HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome 2013; 1: 1-12.
47. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
48. Kang DW, Park JG, Ilhan ZE, et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One 2013; 8: e68322.
49. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2: e01202.
50. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011; 8: 523-531.
51. Schippa S, Conte MP. Dysbiotic events in gut microbiota: impact on human health. Nutrients 2014; 6: 5786-5805.
52. Dillon SM, Lee EJ, Kotter CV, et al. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunol 2015; 7: 983-994.
53. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008; 46: 757-758.
54. Eschbach M, Schreiber K, Trunk K, et al. Long-term anaerobic survival of the opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J Bacteriol 2004; 186: 4596-4604.
55. de Bentzmann S, Plesiat P. The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ Microbiol 2011; 13: 1655-1665.
56. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011; 9: 265-278.
57. Rey FE, Gonzalez MD, Cheng J, et al. Metabolic niche of a prominent sulfatereducing human gut bacterium. Proc Natl Acad Sci 2013; 110: 13582-13587.
58. Peleg AY, de Breij A, Adams MD, et al. The success of acinetobacter species; genetic, metabolic and virulence attributes. PLoS One 2012; 7: e46984.
59. March C, Regueiro V, Llobet E, et al. Dissection of host cell signal transduction during Acinetobacter baumannii-triggered inflammatory response. PLoS One 2010; 5: e10033.
60. Walker RI, Caldwell MB, Lee EC, et al. Pathophysiology of Campylobacter enteritis. Microbiol Rev 1986; 50: 81-94.
61. Bereswill S, Fischer A, Plickert R, et al. Novel murine infection models provide deep insights into the 'menage a trois' of Campylobacter jejuni, microbiota and host innate immunity. PLoS One 2011; 6: e20953.
62. Flint HJ, Bayer EA, Rincon MT, et al. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 2008; 6: 121-131.
63. Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010; 105: 2420-2428.
64. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.
65. Dillon SM, Manuzak JA, Leone AK, et al. HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol 2012; 189: 885-896.
66. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-625.
67. Troy EB, Kasper DL. Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Front Biosci 2010; 15: 25-34.
68. Perez-Santiago J, Gianella S, Massanella M, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS 2013; 27: 1921-1931.
69. Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013; 123: 903-907.
70. LeBlanc JG, Milani C, de Giori GS, et al. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 2013; 24: 160-168.
71. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrateproducing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1-8.
72. Rey FE, Faith JJ, Bain J, et al. Dissecting the in vivo metabolic potential of two human gut acetogens. J Biol Chem 2010; 285: 22082-22090.
73. WuGD, Chen J, Hoffmann C, et al. Linking long-termdietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108.
74. Lozupone CA, Rhodes ME, Neff CP, et al. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes 2014; 5: 562-570.
75. Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol 2015; 8: 760-772.
76. Guandalini S, Cernat E, Moscoso D. Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. Benef Microbes 2014; 6: 209-217.
77. Tojo R, Suarez A, Clemente MG, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014; 20: 15163-15176.
78. Kandasamy S, Chattha KS, Vlasova AN, et al. Lactobacilli and bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. Gut Microbes 2014; 5: 639-651.
79. Heilpern D, Szilagyi A. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, prebiotics and synbiotics. Rev Recent Clin Trials 2008; 3: 167-184.
80. Murphy EC, Frick IM. Gram-positive anaerobic cocci: commensals and opportunistic pathogens. FEMS Microbiol Rev 2013; 37: 520-553.
81. Kumar P, Luo Q, Vickers TJ, et al. EatA, an immunogenic protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin. Infect Immun 2014; 82: 500-508.
82. Nava GM, Carbonero F, Croix JA, et al. Abundance and diversity of mucosaassociated hydrogenotrophic microbes in the healthy human colon. ISME J 2012; 6: 57-70.
83. Levitt MD, Furne J, Springfield J, et al. Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest 1999; 104: 1107-1114.
84. Loubinoux J, Bronowicki JP, Pereira IAC, et al. Sulfate-reducing bacteria in human feces and their association with infammatory bowel diseases. FEMS Microbiol Ecol 2002; 40: 107-112.
85. Handley SA, Thackray LB, Zhao G, et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012; 151: 253-266.
86. Mukherjee PK, Chandra J, Retuerto M, et al. Oral mycobiome analysis of HIVinfected patients: identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog 2014; 10: e1003996.
87. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
88. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
89. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2, 3- dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2: 32ra36.
90. Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol 2012; 5: 646-657.
91. Klatt NR, Brenchley JM. Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS 2010; 5: 135-140.
92. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112: 2826-2835.
93. Dillon SM, Lee EJ, Kotter CV, et al. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunol 2015. doi: 10.1038/mi.2015.33.
94. Macpherson AJ, Geuking MB, McCoy KD. Homeland security: IgA immunity at the frontiers of the body. Trends Immunol 2012; 33: 160-167.
95. Macpherson AJ, Koller Y, McCoy KD. The bilateral responsiveness between intestinal microbes and IgA. Trends Immunol 2015; 36: 460-470.
96. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336: 1268-1273.
97. Trama AM, Moody MA, Alam SM, et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe 2014; 16: 215-226.
98. Seaton KE, Ballweber L, Lan A, et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One 2014; 9: e101863.
99. Jee J, Bonnegarde-Bernard A, Duverger A, et al. Neutrophils negatively regulate induction of mucosal IgA responses after sublingual immunization. Mucosal Immunol 2015; 8: 735-745.
100. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 2012; 10: 66-78.
101. d'Ettorre G, Ceccarelli G, Giustini N, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the 'Probio-HIV' clinical trial. PLoS One 2015; 10: e0137200.
102. Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients -a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr 2015; 68: 256-263.
103. Gori A, Rizzardini G, Van 't Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the 'COPA' pilot randomized trial. Mucosal Immunol 2011; 4: 554-563.
104. Ortiz AM, Klase ZA, DiNapoli SR, et al. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. Mucosal Immunol 2015. doi: 10.1038/mi.2015.75.
105. Kristoff J, Haret-Richter G, Ma D, et al. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest 2014; 124: 2802-2806.
106. Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 2014; 210: 1549-1554.
107. Byakwaga H, Kelly M, Purcell DF, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011; 204: 1532-1540.
108. Dyavar Shetty R, Velu V, Titanji K, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122: 1712-1716.